{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T11:13:58Z","timestamp":1726312438458},"reference-count":6,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,5,29]],"date-time":"2008-05-29T00:00:00Z","timestamp":1212019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1111\/j.1365-2125.2008.03235.x","type":"journal-article","created":{"date-parts":[[2008,5,29]],"date-time":"2008-05-29T11:13:47Z","timestamp":1212059627000},"page":"137-138","source":"Crossref","is-referenced-by-count":6,"title":["Suggestions for effective contraception in isotretinoin therapy"],"prefix":"10.1111","volume":"67","author":[{"given":"Antonios I.","family":"Kanelleas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Berth\u2010Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,12,22]]},"reference":[{"key":"e_1_2_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02837.x"},{"key":"e_1_2_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507133330206"},{"key":"e_1_2_3_4_2","unstructured":"MitchelAA Van BennekomCM LouikC.An assessment of the Accutane (isotretinoin) Pregnancy Prevention Program. FDA Dermatologic Drugs Advisory Committee Meeting Gaithersburgh MD September 18 2000. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/slides\/3639s1i.ppt(last accessed 4 September 2001)."},{"key":"e_1_2_3_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246134"},{"key":"e_1_2_3_6_2","unstructured":"Committee for Proprietary Medicinal Products (CPMP).Committee for Proprietary Medicinal Products (CPMP) summary information on a referral opinion following an arbitration pursuant to Article 29 of Directive 2001\/83\/EC for Isotretinoin\/Lurantan\/Trivane\/Rexidal\/Scheritonin (see Annex I). International Non\u2010Proprietary Name (INN): Isotretinoin. London 17 October 2003. CPMP\/2811\/03."},{"key":"e_1_2_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2007.10.005"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2008.03235.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2008.03235.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:31:23Z","timestamp":1697455883000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2008.03235.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,22]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1365-2125.2008.03235.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03235.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,22]]}}}